Gnosis to announce ibSium clinical results at UEG Week

Published: 6-Oct-2020
Regulatory Research & Development

UEG Week will be hosted on United European Gastroenterology's interactive congress platform, enabling live interaction with experts

Gnosis by Lesaffre will be exhibiting its latest clinical results at the Virtual Week 2020 organized by UEG (United European Gastroenterology) from October 11th to 13th. The results reinforce the efficacy of IbSium to alleviate gastrointestinal symptoms and improve quality of life.

IbSium is Gnosis’s patented probiotic yeast S. cerevisiae CNCM I-3856. UEG Week represents an opportunity to learn more about one of the most documented probiotic for a daily and complete digestive comfort.

“Saccharomyces cerevisiae CNCM I-3856 in IBS predominant constipation: a randomized, double-blind, placebo-controlled, multicentre clinical trial” is the title of the poster that will be held by Arnaud Bourreille, Gastroenterologist at the Institute for Digestive Tract Diseases.

Interested readers can register at the following link: https://ueg.eu/create-account

  • Companies:
  • Gnosis by Lesaffre
See more

You may also like

Training & Education

Gnosis by Lesaffre's Vitamin K2 Scientific Advisory Committee share this year's findings

Read more
In the K2SAC's third meeting, experts discussed the potential of vitamin K2 in healthy ageing and cognitive health, while also looking at necessary future endeavours

Trending Articles

  1. Astaxanthin gives athletes the edge Natural astaxanthin is an excellent nutrient for athletes and active people; it can help them in several important ways
  2. Indian government-affiliated experts call for tighter nutraceutical regulations The panel has advised that certain dietary supplement and nutraceutical products should be placed under the remit of the drug regulatory board, CDSCO
  3. Vitamin D during pregnancy: study reveals the long-term bone health benefits of maternal supplementation The children of mothers who take vitamin D during their pregnancy have significantly better bone mineral density, bone mineral content and lean mass compared to placebo
  4. Brightseed's Forager AI platform named as one of TIME's Best Inventions of 2024 The AI-powered software can help companies to identify new bioactives, as well as novel uses for them, allowing nutraceutical, functional food and dietary supplement companies to create innovative products
  5. Alland & Robert showcases innovation for a healthier tomorrow Visit Alland & Robert at Fi Europe to discover natural and sustainable solutions for better diets

Upcoming event

Fi Europe 2024

19-21 November 2024 | Exhibition | Frankfurt, Germany See all

You may also like

Training & Education

Gnosis by Lesaffre's Vitamin K2 Scientific Advisory Committee share this year's findings

In the K2SAC's third meeting, experts discussed the potential of vitamin K2 in healthy ageing and cognitive health, while also looking at necessary future endeavours
Ingredients

Vitamin K2, calcium and vitamin D as the holy trifecta for bone health

With World Osteoporosis Day approaching, Gnosis by Lesaffre highlights the importance of vitamin K2 in bone health
Ingredients

Vitamin K2 and folate supplementation enhance cognitive health in older adults, study finds

Vitamin K2 and folate intake are associated with enhanced cognition though, alarmingly, 75% of the US population were lacking in serum K2 in a NHANES 2003-2006 study
Ingredients

New MenaQ7 K2 cardio study in kidney patients published

TReVasc-HDK Trial examined the efficacy of K2 supplementation in reducing vascular calcification progression in haemodialysis patients, offering new insights on appropriate dosing
Ingredients

Gnosis sponsors university programme on vitamin K2

The company will be sponsoring an Industrial PhD programme at Maastricht University focusing on the role of vitamin K2 in cardiovascular health
Ingredients

MenaQ7 Vit K2 migraine clinical trial starts as potential therapy

Building off clinical evidence showing Vitamin K2 impacts arterial stiffness, a new 6-month trial has been launched that could present a viable therapy for migraine patients
Research & Development

Research shows women’s need for K2 to protect heart health

Reproductive factors and menopause found to increase the risk of developing heart disease in women
Subscribe now